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Background. Streptokinase is a routinely used thrombolytic agent that is immunogenic and relatively inefficient toward platelet-rich thrombus, whereas staphylokinase is a poorly studied fibrinolytic agent. Here, the comparative immunogenicity and thrombolytic properties toward arterial platelet-rich thrombus and venous whole blood clots of streptokinase and recombinant staphylokinase were studied in baboons.
Methods and Results. The inhibitory capacity of baboon plasma (in a human plasma-based clot lysis assay) was 039±0. 25 ,gg streptokinase and 0.04±0.05 jag recombinant staphylokinase per milliliter of plasma (mean±+SD, n=9). Intravenous infusion over 1 hour of0300 mg/kg of streptokinase at 0, 1, 2,3, and 5 weeks in five baboons given heparin and the antiplatelet agent ridogrel increased the streptokinaseneutralizing titer from 0.22±0.18 pg/mL plasma at baseline to 3.8±4.4 gg/mL after 2 weeks (p=0.043 versus baseline by Wilcoxon signed rank test) and to 4.4±4.6 jtg/mL after 5 weeks, whereas the thrombolytic potency toward a`PI-fibrin-labeled plasma clot inserted into an extracorporeal arteriovenous loop was reduced from 84±7% at baseline to 45±8% after 2 weeks and to 36±8% after 5 weeks (p<0.01 versus baseline). Administration over 1 hour of 0.065 mg/kg recombinant staphylokinase at 0, 1, 2, 3, and 5 weeks in four baboons did not induce measurable staphylokinase-neutralizing activity in three of the four animals after 5 weeks. In the fourth baboon, a staphylokinase-neutralizing activity of 0.8 and 1.5 ,ug/mL was found at 3 and 5 weeks, respectively. Repeated staphylokinase administration was not associated with inhibition of clot lysis (43+4% lysis at baseline, 52+9%o at 3 weeks, and 61+14% at 5 weeks; p=NS versus baseline). Repeated administration of streptokinase but not of staphylokinase caused a marked (>50%) decrease in blood pressure, requiring administration of steroids and intravenous fluids, and a marked increase in leukocyte count and hemoglobin concentration. Intravenous infusion of streptokinase or recombinant staphylokinase over 1 hour in doses ranging between 0 and 1.0 mg/kg in three groups of four baboons each induced dose-dependent lysis of a 1"I-fibrinlabeled autologous jugular vein blood clot (50% lysis requiring 0.140 mg/kg streptokinase and 0.058 mg/kg recombinant staphylokinase, representing equimolar amounts of 3.25 nmol/kg) without systemic fibrinogen depletion. The thrombolytic potency toward platelet-rich arterial thrombus of streptokinase and recombinant staphylokinase were studied in a femoral arterial eversion graft model. Arterial recanalization with recombinant staphylokinase was more frequent and more persistent than with streptokinase (all p<0.05). Intravenous infusion of 1.0 mg/kg streptokinase or 0.25 mg/kg recombinant staphylokinase in two groups of four baboons each given intravenous heparin (200-unit bolus and 50 units . kg`* hr'1) and aspirin (10 mg/kg) did not produce a significant prolongation of the median template bleeding time.
Conclusions. Recombinant staphylokinase has a thrombolytic potency toward jugular vein blood clots in baboons comparable to that of streptokinase, but it is less immunogenic and less allergenic and it does not induce resistance to lysis upon repeated administration; it is significantly more efficient than streptokinase for the dissolution of platelet-rich arterial eversion graft thrombi. Recombinant staphylokinase, which can be easily obtained in active form by expression in Escherichia coli, may constitute a potentially useful alternative to streptokinase for the treatment of acute myocardial infarction. (Circulation 1993;87:996-1006) KEY WORDs * streptokinase * staphylokinase * thrombus T liahrombolytic therapy with intravenous infusion of thrombolytic agents are streptokinase and recombinant plasminogen-activating substances has become tissue-type plasminogen activator (rt-PA). Streptokian established treatment for patients with acute nase is inexpensive but immunogenic and relatively myocardial infarction.1 The most frequently used inefficient for early coronary artery recanalization.2,3 rt-PA is not immunogenic and is more efficient than streptokinase for early coronary artery recanalization, but it is expensive. Thus, thrombolytic agents or strategies with a better benefit/cost or benefit/risk ratio would be desirable.
Staphylokinase, a protein produced by certain strains of Staphylococcus aureus, has been known for more than 40 years to have profibrinolytic properties,4 but its potential as a thrombolytic agent has not been adequately investigated. Initial in vivo experiments with staphylokinase in dogs have yielded very discouraging results,56 but more recently, we reported that staphylokinase has a potency for venous clot lysis in hamsters and rabbits comparable to that of streptokinase.7 To delineate the potential of staphylokinase for thrombolytic therapy in humans, we have developed production and purification methods for recombinant staphyloki-nase8 and evaluated its thrombolytic potency in a pulmonary embolism model in hamsters and its immunogenicity in dogs.9 These studies suggested that recombinant staphylokinase is relatively more potent than streptokinase toward platelet-rich clots and is potentially less immunogenic. However, the questionable representativity of pulmonary plasma clots as a model for platelet-rich arterial thrombosis and the unusually high sensitivity of the dog to fibrinolytic activation with staphylokinase cast doubt on the extrapolation of these findings to humans. Therefore, in the present study, the comparative immunogenicity and thrombolytic properties toward venous whole blood clots and toward platelet-rich arterial thrombus of streptokinase and recombinant staphylokinase were studied in baboons.
Methods

Proteins and Reagents
Streptokinase (Streptase) was purchased from Hoechst (Brussels, Belgium); its concentration was determined from the activity on the label, assuming a specific activity of 100,000 units/mg. "'I-labeled fibrinogen was purchased from Amersham (Buckinghamshire, England). Plasma was pooled human or baboon plasma obtained from at least five healthy blood donors or untreated baboons. Bovine thrombin was obtained from Sigma (St. Louis, Mo.) and aprotinin (Trasylol) from Bayer (Leverkusen, Germany). Natural staphylokinase was isolated and characterized as described elsewhere.8 Recombinant staphylokinase, produced by Escherichia coli JM83 cells transformed with a recombinant pUC19-based plasmid containing the 2.9 kb HindIII restriction fragment obtained from S aureus genomic DNA,10 was isolated from conditioned cell culture broth by a modified version of a previously described procedure.8 This modified purification method, to be described in more detail elsewhere, consisted of adsorption on SP-Sephadex with pH gradient elution, chromatography on SP-Sephadex with NaCl gradient elution, and gel filtration on Sephacryl S-300. It yielded virtually homogeneous recombinant staphylokinase with M, 18,000, with very low endotoxin content (< 10 units/mL) and physicochemical and biochemical properties very similar to those of the materials described elsewhere.8.1' The concentration of recombinant staphy-which was calibrated against natural staphylokinase.8 Conversion from gravimetric to molar amounts was carried out on the basis of molecular weights of 43,000" and 18,000,8 respectively.
Streptokinase/Staphylokinase Neutralizing Activity in Baboon Plasma
A streptokinase/staphylokinase neutralizing activity test, performed as previously described,'4 was applied to baboon plasma and, in control experiments, to human plasma. Increasing concentrations of streptokinase or recombinant staphylokinase (50-,uL volumes containing 0.2-1,000 1£g/mL) were added to 350 ,uL citrated plasma, immediately followed by addition of 100 ,tL of a mixture containing thrombin (50 National Institutes of Health [NIH] units/mL) and CaCl2 (25 mM) . The plasma clot lysis time was measured and plotted against the concentration of streptokinase or recombinant staphylokinase. From this curve, the concentration of plasminogen activator that produced complete clot lysis in 20 minutes was determined and defined as the streptokinase/staphylokinase neutralizing activity.
Alternatively, mixtures of 300 ,uL citrated human plasma and 50 ,uL of buffer, baboon plasma, protein A-Sepharose-adsorbed (Ig-depleted) baboon plasma, or baboon Ig solution (protein A-Sepharose eluate) was used instead of 350 ,uL baboon plasma. The streptokinase-neutralizing or staphylokinase-neutralizing activity titer was defined as the difference in concentration required to obtain lysis in 20 minutes with the mixtures of 300 ttL human plasma and 50 ,uL buffer and those of 300 ,uL human plasma and 50 ,uL of either baboon plasma, protein A-Sepharose-adsorbed baboon plasma, or baboon Ig solution. The neutralizing activity titer was expressed in micrograms of streptokinase or recombinant staphylokinase neutralized per milliliter of the mixture added to the human plasma.
Extracorporeal Loop Thrombosis Model in the Baboon
The thrombolytic properties of repeated infusions of streptokinase or recombinant staphylokinase were compared in baboons (Papio hamadryas) with 0.3 mL 'Ifibrin-labeled homologous plasma clots inserted into an extracorporeal arteriovenous loop. An exposed anterior tibial artery was catheterized with a 4F catheter (Portex White, Portex, Hythe, England) and connected via two hypodermic syringes to a catheterized saphenous vein. The blood flow through the extracorporeal loop was maintained at 10 mL/min with a peristaltic pump. A clot was introduced into each of the two syringes. The plasma clots were prepared by mixing 0.3 mL pooled baboon plasma with a trace amount (approximately 1.5 ,uCi) of "'I-labeled human fibrinogen solution (Amersham) and 0.07 mL of a mixture of bovine thrombin (15 NIH units per milliliter) and 0.5 M CaCl2 and incubation for 30 minutes at 37°C. Ten minutes before the start of the infusion, 1 mg/kg ridogrel (a combined thromboxane synthase inhibitor and prostaglandin endoperoxide receptor antagonist)15 was administered as an intravenous bolus to prevent platelet deposition in the extracorporeal loop. The baboons were anticoagulated with heparin (300 units/kg followed by a continuous infusion of 60 units . kg-' * hr-1 throughout the experiment). The animals were randomly allocated to intralokinase was determined by the Bradford protemi assay. 12 venous administration of 0.300 mg/kg streptokinase or 0.065 mg/kg recombinant staphylokinase given as a 10% bolus and an infusion of the remaining 90% over 1 hour.
Thrombolysis was quantitated 30 minutes after the end of the infusion by determination of the residual radioactivity in each of the two syringes. Alternatively, the rate of clot lysis was monitored continuously by external gamma counting, as described previously.16 No significant differences between the results obtained by isotope recovery and by external scanning were observed. The mean values of the two measurements obtained by isotope recovery were used for statistical analysis.
Jugular Vein Clot Lysis With Streptokinase in the Baboon
In a preliminary series of dose-finding experiments, the thrombolytic properties of streptokinase toward a jugular vein whole blood clot were established in baboons. A '25I-fibrin-labeled autologous whole blood clot was produced in an isolated jugular vein segment using procedures for anesthesia and surgery as described in detail below. All animals received intravenous heparin (300 units/kg bolus followed by infusion of 60 units . kg`* hr-') just before release of the vessel clamp.
Streptokinase was administered intravenously as a 10% slow intravenous injection followed by continuous infusion of the remaining 90% dose over 1 hour. Thrombolysis was quantitated 30 minutes after the end of the infusion by determination of the residual radioactivity in the jugular vein segment or by external gamma counting. In four baboons, the rate of spontaneous clot lysis was followed by external gamma counting for 90 minutes before infusion of the thrombolytic agent to obtain a background value. Blood samples were taken before the start of the experiment and at 30, 60, and 90 minutes. These samples were used for measurement of radioactivity, fibrinogen,17 a2-antiplasmin,'8 and activated partial thromboplastin time.
The thrombolytic potency of streptokinase was determined by fitting of the individual values of the percent lysis versus dose in milligrams per kilogram of body weight, with the exponentially transformed sigmoidal function as described in detail below.
Thrombolysis in Baboons With a Combined
Platelet-Rich Femoral Arterial Eversion Graft Thrombus and a Jugular Vein Whole Blood Clot
The venous blood clot was produced in a jugular vein, essentially as previously described in the rabbit.'9 Adult baboons were premedicated with 10 mg/kg ketamine and 50 jig/kg atropine intramuscularly, anesthetized with 15 mg/kg intravenous sodium pentobarbital followed by 30-60-mg boluses when needed, intubated, and artificially ventilated. The jugular vein was isolated, and all side branches were carefully ligated except for a predominant side branch that was cannulated. After introduction of a woolen thread into the lumen, a 5-cm segment of the vein was isolated between two vessel clamps, emptied, and flushed with saline via the side branch catheter. The segment was then filled with a mixture of a trace amount of`PI-labeled human fibrinogen, 0.6-1.2 mL of fresh blood, 2 units of a thrombin were released after the femoral artery occlusion (see below) was stabilized for 60 minutes, and the infusion protocol was started approximately 1 minute later. The radioisotope content of the venous clot was calculated by subtracting from the original amount of "'I injected into the isolated vein segment the radioisotope that was adsorbed on the cotton swabs placed around the vein segments and the radioiodine that was washed out from the thrombus into the bloodstream as determined 1 minute after removal of the clamps. Two hours after the start of the infusion of thrombolytic agent or placebo, the thrombosed segment of the jugular vein was ligated at both sides, removed, and its radioisotope content was measured. The degree of clot lysis was determined as the residual radioactivity in the vein segment and expressed as percentage of the radioactivity originally incorporated in the clot. An isotope recovery balance was determined by comparing the sum of the total blood radioactivity at the end of the experiment (multiplied by a factor of 3 to correct for extravascular distribution) and the radioactivity in the recovered thrombus with that originally present in the clot. Alternatively, the rate of clot lysis was monitored continuously by external gamma counting, as described previously. 16 The arterial thrombosis model was modified from a previously described rabbit femoral arterial eversion graft thrombosis model. 20 On the day before the experiment, a 3-cm segment of the superficial femoral artery of an anesthetized dog weighing 15-25 kg was excised, everted inside out, and immersed in cell culture medium until use on the next day. Catheters were inserted into the brachial veins of the baboon for blood sampling and infusion of drugs. When the venous clot mixture was introduced into the jugular vein (see above), a femoral artery was exposed in the inguinal region; side branches, when present, were ligated. The baseline blood flow in the femoral artery, measured with an ultrasonic flow probe (Transsonic, Ithaca, N.Y.), was 81+± 10 mL per minute (mean±SEM). The everted canine femoral artery segment was then inserted into the transsected femoral artery via two small polyethylene catheters, and the microvascular clamps occluding the proximal and distal ends of the transsected artery were released. A stenosis of the everted segment, which reduced the blood flow to 17+1% of baseline (n=28), was constructed by progressive external constriction with a 3-mm-wide plastic tie (Wrap-it-tie, Sigma). Occlusion of the everted segment occurred within 7+3 minutes (n=28) and persisted for 60 minutes as monitored with the ultrasonic flow probe. The venous vessel clamps were then released, and the infusion protocol was started within approximately 1 minute. The recanalization time, taken as the time from the start of the infusion of thrombolytic agent or saline until reflow of the occluded graft segment, was determined. The blood flow was continuously recorded during 2 hours to document reocclusion or stable reflow.
All animals received intravenous heparin (200 units/kg bolus followed by infusion of 50 units kg`' hr-'for 3 hours) starting just before the release of the femoral artery vessel clamps, and intravenous ridogrel (2.5 mg/kg bolus and 2.5 mg/kg over 60 minutes) was given at the start of the infusion of thrombolytic agent. Baboons with stable arterial graft occlusion for 60 minutes were assolution, and 10 mM CaCl2. The venous vessel clamps signed to infusion of streptokinase or recombinant staph-ylokinase. The drugs were given intravenously as 10% boluses and infusion of the remaining 90% over 60 minutes. Four additional baboons given heparin and ridogrel but without thrombolytic agent were also studied and used as controls.
During the experiments, a controlled heating pad was used to keep the body temperature at 370C. One hour after the end of the infusion, the everted canine arterial segment was excised and fixed in 10% formalin. The fixed arterial segments were later embedded in parafin, sectioned longitudinally, stained with hematoxylin and eosin, and evaluated microscopically. All catheters were then withdrawn, and the wounds were sutured. When spontaneous respiration had returned, the trachea tubes were removed, and the animals were returned to their cages. To maintain hydration, 50 mL of 0.9% NaCl and 50 mL of 5% glucose solution was infused. Ampicillin (1 g i.m.) or chloramphenicol (1 g i.v.) was administered.
Template bleeding times were measured at baseline and at 30, 60, and 120 minutes after the start of the infusion of study drugs. The bleeding time incision was made using an automated spring-loaded device (Simplate-II, General Diagnostics, Morris Plains, N.J.) applied to the palmar surface of the arm. The region of the incision site was washed, shaved, and dried before performance of the first bleeding time. Blood samples were collected on citrate (final concentration, 0.11 M) before, 1 minute after the 10% bolus injection of thrombolytic agent, and at 60 and 120 minutes after the start of the infusion protocol. These samples were used for measurements of platelet count and ex vivo platelet aggregation induced with ADP (20 gM) and the combination of epinephrine (10 1AM) and arachidonic acid (0.25 mM). Plasma was obtained and stored frozen for determination of fibrinogen and a2antiplasmin levels and the activated partial thromboplastin time. Platelet counting was performed on an automatic cell counter (Sequoia Turner Corporation, Mountain View, Calif.). Platelet aggregation was performed within 1 hour after blood sampling using a standard aggregometer (Chronolog Corporation, Havertown, Pa.). Fibrinogen and a2-antiplasmin were measured as described elsewhere. 17, 18 The thrombolytic potency of the agents for jugular vein clot lysis was determined as follows. The individual values of the percent lysis versus dose in milligrams per kilogram of body weight were fitted with the exponentially transformed sigmoidal function lOOc '-l+e -a(e-eb) using the statistical program GRAFIT (Erithacus Ltd., Middlesex, England). The mean±SEM of the parameters c (maximal lysis in percent), b (dose of compound administered in milligrams per kilogram of body weight, at which the rate of clot lysis is maximal), and ac z=-(oe 4 (maximal rate of clot lysis, expressed as percent lysis per milligram of compound infused per kilogram of body weight) were determined. In addition, the dose producing 50% clot lysis was determined by interpolation on the fitted curve. The significance of the differences between these parameters was estimated using the Student's t test. To convert the relative potency parameters expressed gravimetrically to molar amounts (based on a molecular weight of 43,000 for streptokinase and 18,000 for staphylokinase), the b values obtained for recombinant staphylokinase, relative to those for streptokinase, have to be multiplied by a factor of 2.5 and the z values divided by a factor of 2.5.
The significance of the differences between groups were compared using Fisher's exact test for categorical data or the Student's t test for paired or unpaired values. A Kruskal-Wallis nonparametric ANOVA was performed on ranks of the ordered variable of femoral arterial patency, which ranges from 0 (persistent occlusion) to 1 (cyclic reocclusion and reflow after initial recanalization) to 2 (persistent patency after initial recanalization), as determined with the ultrasonic blood flow probe. A Wilcoxon signed rank test was used to compare the results of the antibody titers before and after administration of streptokinase or recombinant staphylokinase. The animal experiments that were conducted conform to the guiding principles of the American Physiological Society and the International Committee on Thrombosis and Haemostasis.21
Effects of Streptokinase and Recombinant Staphylokinase on Template Bleeding Time
The effects of 1.0 mg/kg of streptokinase or of 0.25 mg/kg of recombinant staphylokinase were studied in groups of four anesthetized baboons given intravenous aspirin (10 mg/kg) and heparin (200 units/kg bolus and 50 units/kg over 1 hour). The thrombolytic agents were given 10 minutes after the bolus injection of aspirin and heparin as a 10% bolus injection and a 90% infusion over 60 minutes. Template bleeding times were measured at baseline, 1 minute after the bolus injection of heparin and aspirin, 1 minute after the 10% bolus injection of thrombolytic agent, and 30, 60, 90, and 120 minutes after the start of the infusion of the remaining 90% (total of seven bleeding times).
Results
Streptokinase/Staphylokinase Neutralizing Activity of Plasma
In pooled human plasma, 0.22±0.03 ,ug/mL streptokinase and 0.32±0.03 ,ug/mL recombinant staphylokinase (mean±SD of six repeat assays) were required to produce lysis in 20 minutes. In plasma samples obtained from 56 human healthy volunteers, the concentration of streptokinase required to produce a clot lysis time of 20 minutes was 0.23 ± 0.26 jug/mL plasma (mean ± SD) (Table 1), with individual values ranging from 0.78 to 4.4 ,ug/mL. Comparative values for recombinant staphylokinase were 0.38±0.12 ,ug/mL (mean+SD), with individual values ranging from 0.18 to 0.75 ,ug/mL. In pooled baboon plasma, the concentration of streptokinase required for clot lysis in 20 minutes was 24±13 ,ug/mL (mean±SD; n=3). For recombinant staphylokinase, corresponding values were 1.2±0.06 ,ug/mL (Table 1). The high resistance of baboon plasma toward streptokinase-induced clot lysis persisted after adsorption of pooled baboon plasma with protein A-Sepharose. Furthermore, the reactivity to streptokinase of a mixture of baboon plasma and human plasma (1:1, vol :vol ratio) was similar to that of plain human plasma. This indicates that the high resistance to streptokinase of plasma from baboons not previously treated with this drug was not due to the presence of inhibiting substances but to an intrinsic resistance of the baboon plasma fibrinolytic system to in vitro (but not in vivo; see below) activation with streptokinase.
The streptokinase/staphylokinase neutralizing activity test for the detection of streptokinase-neutralizing or staphylokinase-neutralizing antibodies in baboon plasma was modified using mixtures of 300 uL of human plasma and 50 ,uL of baboon plasma. The antibody titers were defined as the difference in the amount of compound required to lyse in 20 minutes clots composed of mixtures of 300 ,L of human plasma and 50 ,uL of baboon plasma or of 300 ,L of human plasma and 50 ,uL of buffer. The baseline neutralizing antibody titer in repeat assays for pooled plasma or of a number of this assay was 0.22±0.11 ,ug streptokinase per milliliter of pooled baboon plasma, with individual values in nine baboons of 0.39±0. 25 ,tg/mL. No significant difference for lysis with recombinant staphylokinase was observed in mixtures of human plasma with baboon plasma or with buffer.
Effect of Repeated Administration of Streptokinase and Recombinant Staphylokinase on the Neutralizing Activity of Plasma
In five baboons that were given 0.300 mg/kg streptokinase at 0, 1, 2, 3, and 5 weeks, the streptokinaseneutralizing antibody titer increased from 0.22±0.18 ,ug/mL at baseline up to 4.4+4.6 ,g/mL after 5 weeks ( Table 2 ). The probability value of the differences in antibody titers after 2 weeks, by Wilcoxon signed rank test, was 0.043. The antibody titer of a pooled plasma sample from three baboons obtained 1 week after three *Obtained from the animal with increased staphylokinase-neutralizing activity.
(a),p=0.043 vs. baseline by Wilcoxon signed rank test; (b), 0.03±0.06 ,ug/mL in three animals and 0.8 ug/mL in the fourth baboon; (c), 0.10±0.17 gg/mL in three animals and 1.5 Lg/mL in the fourth baboon; (d), 0.14±0.04 ,tg/mL in three animals and 1.7 ,ug/mL in the fourth baboon; (e), p<0.01 vs. baseline. weekly streptokinase administrations was reduced from 5.2 ug/mL to 0.15 jig/mL by adsorption with protein A-Sepharose, with full recovery of the inhibitory activity in the Ig fraction (protein A-Sepharose eluate) ( Table 2 ).
In the four baboons assigned to weekly administration of 0.065 mg/kg recombinant staphylokinase, neutralizing antibodies could not be demonstrated after up to five intravenous administrations in three of the four baboons, whereas in one baboon, the neutralizing titer increased from undetectable at baseline to 0.8, 1.5, and 1.7 jig/mL after 3, 5, and 8 weeks, respectively. No staphylokinase-neutralizing activity could be demonstrated in the Ig fraction of pooled baboon plasma at baseline or in pooled plasma obtained from the three nonreactive baboons at 3 weeks. In the fourth baboon with induction of neutralizing activity at 3 weeks, this activity was fully recovered in the Ig fraction.
Thrombolysis With Repeated Administration of Streptokinase and Recombinant Staphylokinase in Baboons With Plasma Clots Incorporated Into an Extracorporeal Loop
In two groups of four baboons each, with streptokinase administration at a dose of 0.300 mg/kg or recombinant staphylokinase administration at a dose of 0.065 mg/kg repeated at 1, 2, 3, and 5 weeks after the first administration, lysis of plasma clots introduced into an extracorporeal arteriovenous loop was also measured, with results summarized in Table 2 . Lysis with 0.300 mg/kg streptokinase was 84±7% (mean±SEM, n=4) at baseline and 31±13%, 45±8%, 47±9%, and 36±8% at 1, 2, 3, and 5 weeks, respectively, without associated a2-antiplasmin consumption of fibrinogen depletion (data not shown). One animal died in shock shortly after the second administration (week 1). Therefore, in all subsequent experiments, 10 mg/kg hydrocortisone was injected and 50 mL saline and 50 mL 5% glucose was infused intravenously over 10 minutes whenever the blood pressure dropped to below 50% of baseline within 5 minutes after the bolus administration of 0.030 mg/kg streptokinase (10% of the total dose). Furthermore, if the blood pressure had not increased to above 50% of baseline within 10 minutes, a second bolus injection of 10 mg/kg hydrocortisone was administered. Such transient blood pressure drops were encountered in all three remaining animals given streptokinase from the third week on (from 110±3 mm Hg at baseline to 33±18 mm Hg,p<0.02). Streptokinase administration was also associated with significant increases in leukocyte count (from 5.8±1.2x 103 to 21±2.7x103/mm3, p<0.02) and hemoglobin concentration (from 9.3 ±0.2 to 13 ±0.5 g/dl, p<0.02) at weeks 3 and 5.
In the four baboons given 0.065 mg/kg recombinant staphylokinase, clot lysis was 43±4% at baseline and 49±6%, 46±8%, 52±9%, and 61±14% at 1, 2, 3, and 5 weeks, respectively (Table 2) , also without associated a2-antiplasmin consumption or fibrinogen degradation (results not shown). A blood pressure drop necessitating hydrocortisone and fluid administration was not encountered in any of the animals, and no significant increases in leukocyte count and hemoglobin concentra-
Thrombolytic Properties of Streptokinase in Baboons With Jugular Vein Thrombosis
An initial dose-response curve with intravenous infusion over 60 minutes of streptokinase was established in baboons with an autologous whole blood clot introduced in the jugular vein. The animals were anticoagulated with heparin but were not given antiplatelet agents. In four control experiments, background lysis at 90 minutes as determined by continuous external gamma counting was 3±1%, corresponding to ex vivo isotope recovery values of approximately 20%. 16 Systemic infusion of streptokinase resulted in progressive dose-dependent clot lysis. The extent of clot lysis, as determined by ex vivo isotope recovery, was 37+15% (n=3) with 0.125 mg/kg streptokinase, 54±5% (n=3) with 0.25 mg/kg, and 67±9% (n=3) with 0.50 mg/kg. The isotope recovery balance ranged between 86±10% and 97±3%, confirming that no significant parts of the clot were lost by embolization. Fibrinogen and a2antiplasmin levels did not decrease significantly. The activated partial thromboplastin times prolonged from a baseline value of 58±1 second (mean±SEM, n= 18) to >3 minutes, determined at 60 and 90 minutes after the start of the staphylokinase or streptokinase infusion in all animals (data not shown).
Fitting of the individual dose-response data of clot lysis at 90 minutes with the exponentially transformed sigmoidal function yielded values for z, b, and c of 270±120% per mg/kg dose, 0.11±0.03 mg/kg, and 68±8%, respectively (mean±SEM). Fifty percent clot lysis was obtained at a dose of 0.18 mg/kg. Template bleeding times measured before injection of streptokinase were 3.0±0.35 minutes (mean±SEM, n=9). Bleeding times in the animals given heparin but no antiplatelet agents were prolonged moderately with streptokinase to 7.5±2.4 minutes at the end of the infusion and to 6.4±1.5 minutes at 90 minutes, respectively (data not shown). Clinically apparent bleeding did not occur consistently, although some oozing from the surgical wounds was occasionally observed.
Thrombolysis in Baboons With Combined Femoral
Arterial and Femoral Venous Thrombosis The results of femoral arterial blood flow measurements after the insertion of the everted canine femoral artery segment into the transsected baboon femoral artery are summarized in Table 3 . In all 28 experiments, blood flow was restored after release of the vessel clamp and stabilized at 14-21% of baseline after application of the external constriction without significant difference between any of the groups. Graft occlusion persisting for 60 minutes occurred in all animals, usually within 30 minutes.
In four control experiments with ridogrel and heparin but no thrombolytic agent, arterial occlusion persisted throughout the observation period. Results obtained with infusion of streptokinase at doses of 0.25-1.0 mg/kg or with recombinant staphylokinase at doses of 0.063-0.25 mg/kg over 60 minutes in groups of four baboons are summarized in Table 3 . The time course of the femoral artery recanalization in the individual animals is schematically represented in Figure 1 . The results of femoral arterial patency during the 2-hour observation period after the start of the infusion prototion were observed. Data represent mean±SEM. *In animals with persistent occlusion, the reflow time was assigned a value at 120 minutes for calculation of the mean±SEM. tPO, persistent occlusion; CR, cyclic reocclusion and reflow after initial reflow; PP, persistent patency after initial reflow. The data of the lO0c individual experiments were used for curve fitting with the function y= ( , b) 'b=dose at which the rate of clot lysis is maximal, expressed in mg/kg; z=maximal rate of clot lysis, expressed as % per mg/kg dose; c=maximal lysis achieved, expressed in %.
p=0.034 for overall differences between groups in the table; p=0.26 for differences between groups within streptokinase; p=0.12 for differences between groups within recombinant staphylokinase; p=0.037 for differences between pooled groups of streptokinase and recombinant staphylokinase; p=0.032 for differences between groups given 1 mg/kg streptokinase and 0.25 mg/kg recombinant staphylokinase; p=0.005, 0.075, and 0.002 for differences between b, z, and c values, respectively. col, categorized as described in "Methods," are summarized in Table 3 .
Statistical analysis of the femoral arterial blood flow data showed no difference in blood flow after clamp release between the different groups (p20.04). The times to reflow within the streptokinase and staphylokinase groups and between the drug regimens were not significantly different (p20.04). A Kruskal-Wallis analysis with patency status, ordered as described in "Methods," yielded a probability value of 0.034 for overall differences between groups. The difference between the groups given streptokinase wasp=0.26 and between the groups given staphylokinase wasp =0.12. The difference between the combined groups given recombinant staphylokinase versus the combined groups given streptokinase was significant (p=0.037). The blood flow at 2 hours was significantly (p=0.024) higher in the animals given 0.25 mg/kg recombinant staphylokinase (12±4%) than in the animals given 1 mg/kg streptokinase (0%). The heart rate and blood pressure were not significantly different between the groups (data not shown).
The results of jugular vein clot lysis measured 30 minutes after the end of the infusion of thrombolytic agent and of the isotope recovery balance are also summarized in Table 3 . In the four control baboons given ridogrel and heparin but no thrombolytic agent, the extent of apparent clot lysis was 17+2%, with a calculated isotope recovery balance of 110±5%. Results of venous clot lysis in the groups given 0.25±1.0 mg/kg streptokinase or 0.063-0.25 mg/kg recombinant staphylokinase are summarized in Table 3 .
Fitting of the dose-response data of venous clot lysis at 90 minutes with the exponentially transformed sigmoidal function (Figure 2 ) yielded values as summarized in Table 3 . The thrombolytic potency of recombinant staphylokinase was significantly higher than that of streptokinase, as revealed by a lower b value (p=0.005) and a higher z value (p=0.075). Fifty percent lysis was obtained with 0.14 mg/kg streptokinase and with 0.058 mg/kg recombinant staphylokinase. On a molar basis, however, the potency of recombinant staphylokinase was very similar to that of streptokinase, both requiring 3.25 nmol/kg to induce 50% clot lysis.
Template bleeding times (Table 4 ) measured before injection of study drugs averaged 3-5 minutes. As expected, the bleeding times increased significantly (p<0.05 by paired t test) but transiently with the combinations of streptokinase or recombinant staphylokinase with ridogrel and heparin. Ex vivo platelet aggregation induced with ADP was moderately inhibited with residual values of 52-96% of baseline (data not shown). The platelet count and plasma fibrinogen and a2-antiplasmin levels did not change significantly in any of the groups (data not shown). Activated partial thromboplastin times were prolonged at least twofold in all experimental groups throughout the initial observation period.
The results of pathological analysis of the everted arterial segments are summarized in Table 5 . In general, the results of the pathological analysis were consistent with those obtained by blood flow measurements. Two exceptions were one animal given 0.50 mg/kg streptokinase (experiment 3) and one animal given 0.25 mg/kg recombinant staphylokinase (experiment 4).
Effects of Streptokinase and Recombinant Staphylokinase on Template Bleeding Time in
Baboons Given Aspirin and Intravenous Heparin
Template bleeding times were determined in two groups of four baboons given intravenous aspirin (10 mg/kg) and heparin (200 units/kg bolus and 50 units/kg over 1 hour) and in addition either 1.0 mg/kg streptokinase or 0.25 mg/kg recombinant staphylokinase over 60 minutes. Injection of aspirin and heparin produced a prolongation of the template bleeding time from 2.53 to 9.30 minutes, whereas the additional infusion of the thrombolytic agents did not cause a significant further prolongation of the template bleeding time. The bleed- ing time prolongation rapidly reversed after the end of the infusion.
Discussion
Thrombolytic therapy consisting of the intravenous administration of plasminogen activators has become an established treatment for thromboembolic complications of cardiovascular disease. 22 The thrombolytic agents that are presently available for clinical use (streptokinase, urokinase, anisoylated plasminogen streptokinase activator complex, single-chain urokinasetype plasminogen activator, and rt-PA) are not uniformly efficacious in recanalizing occluded coronary arteries, and their administration has been associated with the occurrence of bleeding complications and reocclusion. The efficacy for coronary thrombolysis is lower, and systemic activation of the fibrinolytic system is more extensive with the non-fibrin-specific agent streptokinase than with the more fibrin-specific agent rt-PA. Furthermore, treatment with streptokinase is associated with transient hypotension and allergic reactions in approximately 5% of the patients, and its administration boosts antibody formation with refractoriness to repeated therapy for several months.2 In the present study, we have compared the immunogenicity and associated resistance to repeated administration of streptokinase and recombinant staphylokinase in baboons. Because of the potentially different sensitivity of platelet-rich versus platelet-poor clots to lysis with thrombolytic agents,2' we have also compared the thrombolytic potency of streptokinase and recombinant staphylokinase in baboons with a combined jugular vein whole blood clot and a platelet-rich femoral arterial eversion graft thrombosis.
To quantitate streptokinaseand streptokinase-neutralizing activity in baboon plasma, we attempted to use a plasma clot lysis assay previously developed for and successfully applied to the quantitation of streptokinase neutralizing antibodies in human plasma.14 However, it appeared that the baboon fibrinolytic system is very resistant to activation with streptokinase in vitro and that this resistance is unrelated to the presence of antibodies. Indeed, protein A-Sepharose-adsorbed plasma was equally resistant to fibrinolytic activation, as native plasma and the apparent inhibitory activity could not be recovered in the Ig fraction of plasma (protein A-Sepharose eluate). Therefore, a modified version of the assay consisting of a mixture of 85% human plasma and 15% baboon plasma was used, which allowed the demonstration of the presence in baboon plasma of inhibitory substances against streptokinase-induced clot lysis. The inhibitory titer in plasma of animals not previously given streptokinase was 0.39±0.25 jig streptokinase neutralized per milliliter of plasma. Repeated administration of streptokinase caused a marked induc-tion of inhibitory capacity in plasma. The antibody nature of the inhibitors induced with intravenous administration of streptokinase was confirmed by their adsorption with protein A-Sepharose with quantitative recovery in the acid eluate from the gel. Both with this assay as well as with the original reactivity assay, no such preexisting antibodies could be demonstrated for recombinant staphylokinase or induction of antibodies Figure 1 .
after four repeated intravenous administrations in three of four baboons. However, in one baboon, staphylokinase-neutralizing activity could be demonstrated from the third administration on (0.8 jig recombinant staphylokinase neutralized per milliliter of plasma). Repeated administration of 0.300 mg/kg streptokinase was associated with partial resistance to clot lysis within 1 week, whereas no resistance could be documented after repeated administration of 0.065 mg/kg recombinant staphylokinase. The in vivo dose-response curves of jugular vein clot lysis in baboons were very similar for streptokinase and staphylokinase. Our previous in vitro studies using à '-I-fibrin-labeled autologous plasma clot submersed in citrated plasma revealed that 50% clot lysis in 2 hours required 68 nM streptokinase and 17 nM staphylokinase in the human and 370 nM streptokinase and 32 nM staphylokinase in the baboon system. 23 In the present study, we obtained evidence that the relative resistance of the baboon fibrinolytic system to streptokinase is not primarily due to the presence of streptokinase-neutralizing antibodies or of inhibitors but to an intrinsic resistance to activation with streptokinase in vitro.
In baboons with a combined jugular vein blood clot and a platelet-rich femoral arterial eversion graft thrombosis, the equipotent doses of streptokinase and recombinant staphylokinase for venous clot lysis were identical at 0.140 and 0.058 mg/kg (each 3.25 nmol/kg). Thus, although the baboon fibrinolytic system appeared to be much more resistant to activation with streptokinase than with recombinant staphylokinase in vitro, the relative potencies of these agents for venous clot lysis in vivo were very similar. These findings confirm previous observations that static in vitro plasma clot lysis systems may not be representative for in vivo thrombolytic systems. Indeed, a similar lack of correlation between in vitro and in vivo findings has been observed previously for clot lysis with synergistic mixtures of thrombolytic agents24,25 and with tissue-type/urokinase chimeric plasminogen activators.26 Extensive lysis was not associated with extensive fibrinogen degradation and impaired ADP-induced platelet aggregation or with prolongation of the template bleeding time.
In these animals, more frequent and more persistent recanalization of the platelet-rich femoral arterial eversion graft thrombosis was obtained with recombinant staphylokinase than with streptokinase. These findings confirm and extend previous observations in in vitro plasma clot lysis systems,"1 in hamsters with plateletenriched pulmonary emboli, and in dogs with femoral arterial eversion graft thrombosis9 that recombinant staphylokinase is indeed more efficient for dissolution of platelet-rich thrombus. However, even at the highest dose used, the platelet-rich thrombotic material was not always completely removed from the eversed arterial segments. This further supports the hypothesis that platelet-rich arterial clots are indeed very resistant to thrombolysis.20
The infusion of recombinant staphylokinase in baboons was not consistently associated with excessive bleeding as was previously observed by Lewis et al5 in dogs or with excessive fibrinogen breakdown as reported in dogs by Kanai.6 Further prolongation of the template bleeding time with the infusion of 1.0 mg/kg streptokinase or with 0.25 mg/kg recombinant staphylokinase in baboons pretreated with intravenous aspirin and heparin could not be documented.
The potential for fibrin-specific clot lysis with recombinant staphylokinase in humans is not resolved by the present and earlier studies. Recombinant staphylokinase appears to be more fibrin specific than streptokinase in in vitro human plasma clot lysis systems. 27"8 Fibrin specificity of staphylokinase is confirmed in in vivo clot lysis models in hamsters and rabbits7 and now also in baboons. However, in these animal models, fibrin-specific clot lysis is also obtained with streptokinase, which induces extensive fibrinogen breakdown in humans. In addition, other instances have previously been encountered in which relatively fibrin-specific clot lysis in human plasma in vitro could not be achieved at therapeutic doses in vivo.2930 Notwithstanding these limitations in the extrapolation of results obtained in experimental animal models to clinical conditions in humans, the findings of the present study warrant further investigation of the thrombolytic properties of recombinant staphylokinase as an alternative to streptokinase but without its undesirable immunologic side effects. The advantages of recombinant staphylokinase over streptokinase would include reduction or absence of allergic reactions and antibody induction leading to refractoriness to repeated administration, a higher efficacy toward platelet-rich clots, and possibly a lower systemic fibrinogenolytic effect. In addition, recombinant staphylokinase can be obtained easily in active form by expression in E coli without further manipulation. Initial experience in the first five patients with acute myocardial infarction who were treated with 10 mg recombinant staphylokinase over 30 minutes (D. Collen and E. Van de Werf, unpublished observations) revealed coronary artery reperfusion in the absence of fibrinogen breakdown, which confirms some of the anticipations of the present study.
